Effect and mechanism of bacterial lysate on chronic obstructive pulmonary disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054037

Enrollment

Unknown

Registered

2021-12-07

Start date

2021-12-07

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

control group:conventional therapy

Staphylococcus albus tablet group:Oral staphylococcus albus tablets 4 tablets each time, 2 times a day for 3 consecutive months

Staphylococcus and Neisseria Tablets Group:Oral Staphylococcus albicans tablets, 4 tablets each time, 2 times a day for 3 consecutive months

Eligibility

Sex/Gender

All

Age

40 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Meet the GOLD2017 COPD diagnostic criteria (FEV1/FVC 40 years; 3. BMI index is 18kg/m2-36 kg/m^2; 4. The clinical symptoms are stable, and the medication has not changed within 1 month.

Exclusion criteria

Exclusion criteria: Patients with other respiratory diseases (asthma, bronchiectasis, pulmonary fibrosis, etc.), malignant tumors, immune system-related diseases or a history of oral/intravenous hormone therapy within 1 month before enrollment.

Design outcomes

Primary

Measure	Time frame
forced expiratory volume in one second ;The ratio of forced expiratory volume in 1 second to forced vital capacity;Forced expiratory volume in 1 second as a percentage of predicted;gut microbiota;airway microbiota;SIgA;	—

Countries

China

Contacts

Public ContactHan Wei

Qingdao Municipal Hospital

hanw@qdu.edu.cn+86 18561857838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026